Insider trade

Officer sold ~$364K of CORT shares in the open market

Traded Nov 25, 2025 · Filed Nov 27, 2025

Why it stands out

Corcept Therapeutics's Chief Development Officer sold $364K of Corcept Therapeutics shares. The filing does not indicate a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Officer$100K–$500K

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$364,070

Shares × reported transaction price

Timing vs results

21 days after results of Nov 4, 2025, 91 days before results of Feb 24, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	+8.4%	+0.3%	+8.1%
30 days	+0.5%	+0.7%	−0.1%
90 days	−54.9%	+0.9%	−55.8%
180 days	−16.1%	+9.8%	−25.9%

Past results only. Not a forecast.

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $80.81 to $81.085 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.